Practical intricacies surrounding biosimilar adoption
Description: There are many intricacies surrounding the introduction of biosimilars. Here, Simon Cheesman, BPharm, MRPharmS from University College London Hospital (UCLH), London, UK discusses some of these issues, including whether patients need to be re-consented for treatment, the attitudes of health care professionals towards the adoption of biosimilars and the essential role pharmacists will serve. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK. This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.
Shared By : VJHemOnc
Posted on : 12/13/17
Added : 4 months ago